Royalty Pharma, Syndax In $350 M Royalty Funding Agreement

 

• Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenib
• Expected to fund Syndax through profitability; proforma cash approaching $800 million as of June 30

https://www.globenewswire.com/news-release/2024/11/04/2974472/0/en/Royalty-Pharma-and-Syndax-Pharmaceuticals-Enter-Into-350-Million-Royalty-Funding-Agreement-for-Niktimvo.html